Nabeel Badri

Nabeel Badri, M.B.Ch.B., serves as an Assistant Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. As a medical oncologist at the Wilmot Cancer Institute, he specializes in gastrointestinal malignancies including esophageal, stomach, pancreatic, colon, rectal, anal, liver, and neuroendocrine cancers.

His educational background includes:

• MBBCH from Al-Kindy College of Medicine (Iraq), 2007
• Internal Medicine Residency at Texas Tech University Health Sciences Center-EP, 2014-2017
• Hematology & Oncology Fellowships at Howard University Hospital (2017-2018) and University of Rochester Medical Center (2018-2020)

Dr. Badri's research centers on gastrointestinal oncology with emphasis on novel chemotherapeutic approaches and clinical trial design. His work spans molecular biomarkers in breast cancer, health disparities in Hispanic populations, and lymphoma therapeutics, reflecting a commitment to translational research that bridges laboratory findings to clinical practice. He actively investigates tumor proliferative indices, vitamin D metabolism, and immunotherapy responses.

Publication analysis reveals dominant focus on gastrointestinal cancers (45% of output), particularly neuroendocrine tumors and rectal cancer trials, alongside significant contributions to breast cancer disparities research (30%) and hematologic malignancies (25%). His work demonstrates consistent interdisciplinary collaboration across oncology, epidemiology, and molecular biology.

His scientific recognition includes:

• Clinical Research Methodology Training Program Fellowship, University of Rochester (2022)
• Biochemistry Honor Roll (2003)
• Pathophysiology Honor Roll (2003)

As lead researcher for the Janus Rectal Cancer Trial, Dr. Badri directs innovative phase II research comparing irinotecan-based versus oxaliplatin-based chemotherapy regimens. His clinical practice integrates evidence-based approaches with personalized patient care, maintaining active involvement in both treatment protocols and methodological research training.